Aid workers say USAID cuts are putting the lives of children with HIV at risk
Nearly 200 children live in a hillside village on the border of Kampala, Uganda. They are given food, shelter and an education at the Light the Future Foundation, a school and orphanage founded by Patrick Ssenyondo.
The organization provides critical care for HIV-positive children who have been left by their parents in the east African country.
"Most of the children here lost their parents, and those that have them, they can't take care of them," Ssenyondo told ABC News. "They can't pay their tuition, they cannot pay for their medication, they can't pay for food."
The children, who are facing the unimaginable, now have another blockade to survival.
On Jan. 20, President Donald Trump signed an executive order that suspended foreign aid for 90 days. Later came the termination of several foreign aid contracts, which have upended facilities and organizations like the Light the Future Foundation.
Ssenyondo told ABC News that his foundation used to have a month's supply of medication prior to the cuts. Now, he's resorted to rationing the children's medication, only having a week's supply since the cuts have taken place
While no child has died at his center, the children's 28-year-old teacher, Ms. Mary, passed away after Ssenyondo says she wasn't able to access her antiretrovirals -- a result of the USAID cuts.
That's a fate Ssenyondo hopes won't fall on the children. He told ABC News he can't bear to tell them they aren't getting their medications.
"If you tell one child that you know, we are no [longer] getting medication for your AIDS, so you're going to lose your life," Ssenyondo said. "That's something we cannot do. So we keep quiet."
In another part of rural Uganda, Bayo Emmanuel, founder of the Bright Star Orphanage, shared a similar story. The eight HIV positive orphans he cared for got their medication for free prior to the cuts.
After the cuts, Emmanuel said he was told he should turn to the private sector, where he would have to pay for their medication. He couldn't afford all of the children's medication and the orphanage ran out.
One of the children, 14-year-old Migande Andrew, quickly fell ill.
"He got weaker and weaker every day and lost his life in the process," Bayo told ABC News.
The community he loved gathered to say their goodbyes, burying him on Feb. 21.
Uganda has one of the highest rates of HIV in the world. Migande Andrew and Ms. Mary are just two of an estimated 53,000 HIV-related deaths worldwide resulting from US Aid cuts, according to Boston University's PEPFAR Impact Tracker. This tool tracks the impact of the President's Emergency Plan for Aids Relief, created by George W. Bush in 2003 and credited with saving 20 million lives around the globe.
Today, the tool projects more than 9,000 children's lives could be lost globally by the end of 2025 if services aren't restored.
Earlier this year, the Trump administration announced it was terminating 90% of its foreign aid contracts and cutting $60 billion in funding for international programs that support everything from famine relief to fighting infectious diseases like HIV and AIDS.
The administration has denied any lives have been lost in connection to the recent cuts. On Feb. 4, Secretary of State Marco Rubio addressed the cuts during a press conference.
"We've issued waivers because we don't want to see anybody die or anybody be harmed in the short term," he said. "But we're going to conduct a review, and we are going to have foreign aid in this country that is going to further the national interests of the United States."
In a tense May 21 exchange before members of the Senate Foreign Committee, Rubio said he was very proud of the work the administration has done so far with USAID, though he was questioned by several lawmakers as to the severity of the cuts.
Despite the abrupt termination of resources from the U.S., people in Uganda are doing everything they can to keep their communities alive.
To the west of Kampala, a clinic called The Family Hope Center is still running due to the strength and resilience of its workers. Since March, all staff have been working for free.
The center has provided comprehensive HIV care and treatment services since 2005. It's been a lifeline for just under 4,000 patients, who are now unsure of how the center will be funded.
"If we are not working, that means more people are going to get HIV, more people will drop out of care," Mubezi Peruth, a nurse at the center, told ABC News. "So we have to be here to encourage our clients to continue taking the medicine and to teach those that are negative to stay negative through the prevention information we give them."
At the orphanage, Ssenyondo is unsure of what will happen next.
"This is the time when the children need us more," he said. "This is the time when we have to act so much to encourage these children not to lose efforts to fight AIDS."
Aid workers say USAID cuts are putting the lives of children with HIV at risk originally appeared on abcnews.go.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Oakland County issues alert for measles exposure site in Rochester Hills
FOX 2 - The Oakland County Health Division is notifying the public about a Rochester Hills measles exposure site involving a person from another county. The exposure site is a medical office building at 3950 S. Rochester Road at the corner of South Boulevard on Tuesday, June 3, according to a release from the Oakland County Health Division. Anyone there between 8 a.m. and 7:30 p.m. may have been exposed to measles. If you think you were exposed to measles at this location on June 3, Immune Globulin (IG) treatment is effective within six days of exposure for high-risk individuals. Those considered high-risk include women who are pregnant, unvaccinated children under age 5 and those who have a weakened immune system due to illness and disease including diabetes or HIV, malnutrition and/or medications. If you are not eligible for IG, monitor symptoms through June 24. If symptoms develop, call ahead to your health care provider. Individuals born in or before 1957 are considered immune. Measles is a highly contagious, vaccine-preventable disease that is spread by direct person-to-person contact and through the air. The Health Division recommends unvaccinated individuals ages 1 year and older receive a measles vaccination to protect themselves and those around them. Anyone who doesn't have a record of two MMR vaccines, unsure if they've have been vaccinated, or unsure if you've had measles in the past, needs to contact their health care provider. Measles can live for up to two hours in the air where an infected person coughed or sneezed. Symptoms of measles usually begin 7-14 days after exposure, but can appear up to 21 days after exposure, and may include: High fever (may spike to over 104°F Cough Runny nose Red, watery eyes (conjunctivitis) Tiny white spots on the inner cheeks, gums and roof of mouth (Koplik Spots) 2-3 days after symptoms begin. A rash that is red, raised, blotchy; usually starts on face, spreads to trunk, arms and legs 3-5 days after symptoms begin. The MMR vaccine is available through some health care providers, Oakland County Health Division offices in Southfield and Pontiac, and many pharmacies. Health Division offices are located at the following addresses: North Oakland Health Center, 1200 N. Telegraph Road, Building 34 East, Pontiac South Oakland Health Center, 27725 Greenfield Road, Southfield. Health Division clinics hours are Monday, Wednesday and Friday 8:30 a.m. – 5 p.m. Tuesday 9:30 a.m. – 6 p.m. and Thursday 7:30 a.m. – 5 p.m. Visit for more information on measles, or contact Nurse on Call, 8:30 a.m. to 5 p.m. Monday through Friday, at 800-848-5533 or noc@
Yahoo
7 hours ago
- Yahoo
Long-lasting HIV prevention shot heads toward approval
June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month. If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV. Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV. That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported. "We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Johanna Mercier, Gilead's chief commercial officer Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next decade. Many people already say they'd prefer a shot over daily pills. In one survey of more than 500 PrEP users, 95% said they would switch to a long-acting injection. Sales of other long-acting options, like the shot Apretude from GSK, have risen sharply - up 63% in the past year. Even with strong results, Gilead faces several hurdles. One is reaching the people who need PrEP the most. Black Americans represent 39% of new HIV cases but only 14% of current PrEP users. Many people still face stigma or lack insurance coverage, which can limit access. Gilead says reaching underserved groups is a top goal. Most current PrEP users have commercial insurance, but Medicaid will be key for expanding access to lower-income communities. Another concern: Some experts worry the new shot may simply replace current Gilead products, like the daily pill Descovy, which now holds about 40% to 45% of the market. But Gilead says the shot should help expand the overall number of people using PrEP in both the U.S. and abroad. "We're thinking globally about the public health impact we can have," Mercier said. The company is working with governments and health groups in the United Kingdom and low-income countries to raise awareness and make these products more available. More information The National Institutes of Health has more on Pre-Exposure Prophylaxis (PrEP). Copyright © 2025 HealthDay. All rights reserved.


UPI
8 hours ago
- UPI
Long-lasting HIV prevention shot heads toward approval
June 6 (UPI) -- A new vaccine to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month. If approved, the shot -- lenacapavir -- would be given twice a year and could be a big step forward in the fight against HIV. Drugmaker Gilead Sciences tested the shot in a study of women and girls. None of the participants who received the injections got HIV. That early success helped boost Gilead's stock by 73% over the past year, The Wall Street Journal reported. "We know it's challenging to take a daily pill for prevention, and we see an incredible opportunity here," said Johanna Mercier, Gilead's chief commercial officer Right now, more than 400,000 people in the United States use pills to prevent HIV, The Wall Street Journal added. These medications are referred to as PrEP, short for pre-exposure prophylaxis. Gilead expects the number of users to top 1 million by the next decade. Many people already say they'd prefer a shot over daily pills. In one survey of more than 500 PrEP users, 95% said they would switch to a long-acting injection. Sales of other long-acting options, like the shot Apretude from GSK, have risen sharply - up 63% in the past year. Even with strong results, Gilead faces several hurdles. One is reaching the people who need PrEP the most. Black Americans represent 39% of new HIV cases but only 14% of current PrEP users. Many people still face stigma or lack insurance coverage, which can limit access. Gilead says reaching underserved groups is a top goal. Most current PrEP users have commercial insurance, but Medicaid will be key for expanding access to lower-income communities. Another concern: Some experts worry the new shot may simply replace current Gilead products, like the daily pill Descovy, which now holds about 40% to 45% of the market. But Gilead says the shot should help expand the overall number of people using PrEP in both the U.S. and abroad. "We're thinking globally about the public health impact we can have," Mercier said. The company is working with governments and health groups in the United Kingdom and low-income countries to raise awareness and make these products more available. More information The National Institutes of Health has more on Pre-Exposure Prophylaxis (PrEP). Copyright © 2025 HealthDay. All rights reserved.